Humanized mouse

New Research in the Treatment of Parkinson's Disease

Retrieved on: 
Wednesday, December 6, 2023
Parkinson's disease, B cell, Gait, Brain, Research, Alzheimer's disease, Ageing, Freezing, Glioblastoma, PD, Tremor, Patient, Humanized mouse, Nervous system, Wound healing, Heart failure, University, Movement, Ceramic, Burnett School of Medicine, Biomedical sciences, Cognition, UCF, Neurodegenerative disease, Motor disorder, Human, COM, Neurology, Rat, Rigidity, Pharmaceutical industry, Medicine, Disease

The UCF researchers had previously published a study demonstrating that they could increase wound healing using this treatment.

Key Points: 
  • The UCF researchers had previously published a study demonstrating that they could increase wound healing using this treatment.
  • Parkinson's disease is the most frequent motor disorder and the second most frequent neurodegenerative disease after Alzheimer's Disease (AD).
  • The tremor, rigidity, and slowness of movement associated with Parkinson's disease affect up to 10 million people throughout the world.
  • The UCF research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's disease, Parkinson's disease, traumatic brain injury, and heart failure.

CancerVAX CEO Ryan Davies Sits Down with Oncology Research Leader

Retrieved on: 
Monday, March 20, 2023
Mouse, Medical Investigation, University, Doctor of Philosophy, Humanized mouse, CSO, Biotechnology, Cancer, CancerVax, Monogenic, Associate, Science, Huntsman Cancer Institute, The Co Founder, Publication, Supergene, Human biology, Therapy, BYU, Biology, University of Texas System, Pharmaceutical industry, LEHI

After receiving his Ph.D., Dr. Bearss started at the Cancer Therapy Research Center; later, he became Co-Director of Genetically Modified Mice at the University of Arizona Cancer Center.

Key Points: 
  • After receiving his Ph.D., Dr. Bearss started at the Cancer Therapy Research Center; later, he became Co-Director of Genetically Modified Mice at the University of Arizona Cancer Center.
  • Dr. Bearss was an Assistant Professor at the University of Arizona’s Department of Molecular and Cellular Biology before leaving academia for private industry.
  • You can’t pound a round peg into a square hole.”
    CancerVAX CEO Ryan Davies noted his excitement to speak with biotechnology leader Dr. David Bearss, “Dr.
  • As a company focused on the immunology side of cancer treatment, Dr. Bearss’ years of experience and advice are greatly appreciated.”
    For more information about CancerVax, please visit http://www.cancervax.com/ .

Synbal, in collaboration with The La Jolla Institute for Immunology, is awarded a NIH-SBIR grant to develop and characterize a three gene humanized mouse model for Covid-19 research

Retrieved on: 
Thursday, May 27, 2021
Life sciences, Biotechnology, Health sciences, Humanized mouse, La Jolla Institute for Immunology, Biopharmaceutical

Synbal is partnering with La Jolla Institute for Immunology (LJI) to fully characterize the model that will then be made available in early 2022 to the research community to accelerate the development of new therapeutics that can be used to treat this devastating pandemic.

Key Points: 
  • Synbal is partnering with La Jolla Institute for Immunology (LJI) to fully characterize the model that will then be made available in early 2022 to the research community to accelerate the development of new therapeutics that can be used to treat this devastating pandemic.
  • "The mouse models we develop will be important tools for scientists as we develop next generation COVID-19 vaccines and therapies."
  • Synbal, Inc. is a preclinical biotechnology company using its proprietary next-generation gene-editing platform, Active Genetics, to develop genetically complex humanized mouse models for biopharmaceutical research and development.
  • Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Tuesday, May 4, 2021
Rare diseases, Humanized mouse, Methylmalonic acidemia, Medical specialties, Clinical medicine, Medicine

b'LEXINGTON, Mass., May 4, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting being held May 11-14, 2021.

Key Points: 
  • b'LEXINGTON, Mass., May 4, 2021 /PRNewswire/ --LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting being held May 11-14, 2021.
  • Results show high potency in a humanized mouse model and in non-human primates compared to widely used benchmark liver targeting capsids.
  • Results from a mouse model indicate that administration of the mLB-001 genome editing therapy leveraging GeneRide improves disease phenotype and survival in methylmalonic acidemia (MMA).
  • LogicBio\'s cutting-edge sAAVy capsid development platform is designed to support development of treatments in a broad range of indications and tissues.

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

Retrieved on: 
Monday, April 12, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Cancer treatments, Clinical medicine, Drugs, Breakthrough therapy, Antineoplastic drugs, Lung cancer, Cancer immunotherapy, Orphan drugs, Nivolumab, Pembrolizumab, Humanized mouse, Non-small-cell lung carcinoma

Humanized mice were first treated with REQORSA, immunotherapy nivolumab (Opdivo\xc2\xae), or the combination.

Key Points: 
  • Humanized mice were first treated with REQORSA, immunotherapy nivolumab (Opdivo\xc2\xae), or the combination.
  • Next, humanized mice were treated with REQORSA, immunotherapy pembrolizumab (Keytruda\xc2\xae), or the combination.
  • Xenograft tumors from both H1975-parental and H1975-OsiR cells were developed in NSG mice and were treated with osimertinib.
  • The Company\xe2\x80\x99s lead product candidate, REQORSA\xe2\x84\xa2 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC).

GemPharmatech Opens New Operations in United States to House More Than 6000 Research Mouse Models

Retrieved on: 
Monday, February 22, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Humanized mouse, Applied ethics, Animal testing, Science and technology, Science

GemPharmatech ( GPT ) Co., Ltd. announced the establishment of new operations to house more than 6000 mouse models in Massachusetts and California.

Key Points: 
  • GemPharmatech ( GPT ) Co., Ltd. announced the establishment of new operations to house more than 6000 mouse models in Massachusetts and California.
  • GPT is a leading global provider of laboratory animals including cKO/KO and humanized mouse models as research tools supporting drug discovery and pre-clinical research and development.
  • Currently, GPT has a large collection of 15,000+ mouse models and has four existing facilities worldwide.
  • GemPharmatech, Co., Ltd. is a leading provider of animal models and services, especially in the development of humanized animal models, to global pre-clinical R&D communities.

Global Humanized Mice Model Market to 2025 by Service, Type, Immune Checkpoints, Application, End-user, and Region

Retrieved on: 
Thursday, January 21, 2021
Medical specialties, Medicine, Branches of biology, Cancer research, Humanized mouse, Patient derived xenograft, Xenotransplantation, Genetically modified mouse, Humanized antibody, Genetic engineering, Mouse Models of Human Cancer database

The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.

Key Points: 
  • The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.
  • In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market.
  • The Global Humanized Mice Model Market is segmented based on service, type, immune checkpoints, application, end-user, and region.
  • Based on type, the market is fragmented into cell line transplantation model, patient derived xenografts, genetically engineered mouse model and others.

Global Humanized Mice Model Market Report 2020: Historical Years 2015-2018 / Base Year of 2019 / Estimated Year, 2020 / Forecasts 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 20, 2021
Health, Other Health, Humanized mouse, Mouse

The Objectives of the Study:

Key Points: 
  • The Objectives of the Study:
    To analyze and estimate the market size of the Global Humanized Mice Model Market from 2015 to 2018.
  • To estimate and forecast the market size of the Global Humanized Mice Model Market from 2019 to 2025.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the Global Humanized Mice Model Market.
  • To identify key sustainable strategies adopted by market players in the Global Humanized Mice Model Market.

Applications of Liver Humanized Mouse Models in Preclinical Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 30, 2020
Branches of biology, Humanized mouse, Liver, Hepatocyte, Biology, Humanized antibody, Biotechnology, Stem cells

Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes.

Key Points: 
  • Over the past two decades, much progress has been made in the development of mouse models which are able to achieve at least 70% replacement of mouse hepatocytes with human hepatocytes.
  • This has enabled the use of these models for an increasing variety of applications in the preclinical drug development process.
  • The first segment of this webinar will focus on the genetic basis of these liver-humanized mouse models, as well as their historical development and characterization.
  • For more information or to register for this event, visit Applications of Liver Humanized Mouse Models in Preclinical Drug Development.

Global Humanized Mice Model (Cell-line transplantation model, Patient based xenografts, Genetically Engineered Mice, Others) Market, Competition, Forecast & Opportunities, 2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 16, 2020
Health, Other Health, Articles, Medical specialties, Medicine, Cancer research, Patient derived xenograft, Xenotransplantation, Humanized mouse, Genetically modified mouse, Humanized antibody, Genetic engineering, Mouse Models of Human Cancer database

The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.

Key Points: 
  • The Global Humanized Mice Model Market is driven by continuous research and development activities in pharmaceutical companies across the globe.
  • In addition to this, increasing investments for research in laboratories and institutes is positively impacting the growth of the market.
  • The Global Humanized Mice Model Market is segmented based on service, type, immune checkpoints, application, end-user, and region.
  • Based on type, the market is fragmented into cell line transplantation model, patient derived xenografts, genetically engineered mouse model and others.